Design, Synthesis, and Biological Evaluation of BODIPY-Caged Resiquimod as a Dual-Acting Phototherapeutic
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Eslam Roshdy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, Higashi-Hiroshima City, Hiroshima 739-8526, Japan. Hauptthemen laut MEDLINE: Boron Compounds, Imidazoles, Drug Design, Photosensitizing Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Corporation.
Abstract (Originalsprache)
Resiquimod, an imidazoquinoline scaffold, exhibits potent immunotherapeutic activity but is associated with off-target effects, limiting its clinical utility. To address this limitation, we developed a novel BODIPY-caged resiquimod that is responsive to red light, combining photocaging and photodynamic therapy functionalities. Molecular docking studies guided identification of the optimal caging site for resiquimod, effectively masking its immune activity. BODIPY-caged resiquimod remained inactive under dark conditions, effectively masking resiquimod's immunostimulatory effects. However, red light irradiation precisely uncaged resiquimod, inducing robust immune activation, even in the presence of N-acetyl cysteine as an antioxidant. Notably, the attachment of resiquimod to BODIPY reduced the dark toxicity typically associated with BODIPY as a photosensitizer. In 3D spheroid models of HeLa and A549 cells, BODIPY-caged resiquimod demonstrated spatiotemporal control over cytotoxicity, significantly enhancing cell death only upon irradiation. This dual-function therapeutic approach highlights a "win-win" strategy: precise, red-light-mediated control of immune activation and photodynamic efficacy with reduced collateral toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, Higashi-Hiroshima City, Hiroshima 739-8526, Japan.
- Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
- Department of Pharmacology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima 734-8553, Japan.
- Graduate School of Integrated Sciences for Life, Hiroshima University, 1-3-1 Kagamiyama, Higashi-Hiroshima, Hiroshima 739-8526, Japan.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.
- Avian Research Center, King Faisal University, Al Hofuf, Al-Ahsa 31982, Saudi Arabia.
ORCID-Profile: Eslam Roshdy, Haruko Takahashi, Yutaka Kikuchi, Ismail Celik, Manabu Abe
Förderung
- Japan Science and Technology Corporation
Zitieren
APA
Roshdy, E., Taniguchi, H., Nakamura, Y., Takahashi, H., Kikuchi, Y., Celik, I., Mohammed, E. S. I., Ishihara, Y., Morioka, N., & Abe, M. (2025). Design, Synthesis, and Biological Evaluation of BODIPY-Caged Resiquimod as a Dual-Acting Phototherapeutic. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02606
Vancouver
Roshdy E, Taniguchi H, Nakamura Y, Takahashi H, Kikuchi Y, Celik I, et al. Design, Synthesis, and Biological Evaluation of BODIPY-Caged Resiquimod as a Dual-Acting Phototherapeutic. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02606
BibTeX
@article{Roshdy2025,
author = {Roshdy, Eslam and Taniguchi, Haruto and Nakamura, Yoki and Takahashi, Haruko and Kikuchi, Yutaka and Celik, Ismail and Mohammed, Elsayed S I and Ishihara, Yasuhiro and Morioka, Norimitsu and Abe, Manabu},
title = {Design, Synthesis, and Biological Evaluation of BODIPY-Caged Resiquimod as a Dual-Acting Phototherapeutic},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02606}
}
EUVIMED